oral semaglutide vs trulicity Dosing Patterns of Dulaglutide and in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study | Advances in Therapy Lesson: Oral Semaglutide: A New
Description
It is not recommended during pregnancy
Retatrutide (LY3437943), developed by Eli Lilly, is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
Patients transitioning to semaglutide from tirzepatide should begin with the lowest possible dose of semaglutide (0.25 mg weekly), regardless of their previous tirzepatide dosage
BMJ (2014) 348:g2366
Lower doses correlate with reduced nausea and diarrhea, a benefit highlighted in Verywell Healths overview of microdosing
When glucose levels stabilize, the metabolic pressure that promotes fat storage may decrease
